A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

NCT03879122 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer

Interventions

DRUG: Ipilimumab 5 MG/ML
DRUG: Nivolumab 10 MG/ML
DRUG: Docetaxel
DRUG: ADT (androgen deprivation therapy)

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]
[object Object]